Anti-HCMV compositions and methods
This document relates to compounds useful as agents for preventing or treating human cytomegalovirus (HCMV) infections.
1. A composition comprising a compound of formula
wherein:
X is NH or O;
R 1 and R 7 are independently selected from H, halo, lower straight chain or branched alkyl, and OR 6 ;
R 3 , R 4 , and R 5 are independently selected from H, halo, —CN, lower straight chain or branched alkyl, and OR 6 ;
each R 6 is independently selected from H, lower straight chain or branched alkyl;
n is 1, 2 or 3;
the
group is substituted with 0, 1 or 2 groups independently selected from halo, —CN, lower straight chain or branched alkyl; and
at least one of R 3 , R 4 , or R 5 is in the ortho position and selected from the group consisting of halo, —CN, a straight chain or branched alkyl of 1 to 4 carbon atoms, and a straight or branched alkoxy of 1 to 4 carbon atoms;
or a pharmaceutically acceptable salt thereof.
2. The composition of claim 1 , wherein the
group is:
wherein:
R 8 is selected from H, halo and —CN.
3. The composition of claim 2 , wherein at least two of R 3 , R 4 , or R 5 is in the ortho position and selected from the group consisting of halo, —CN, a straight chain or branched alkyl of 1 to 4 carbon atoms, and a straight or branched alkoxy of 1 to 4 carbon atoms.
4. The composition of claim 2 , wherein R 2 is selected from halo, lower straight chain or branched alkyl, and OR 6 .
5. The composition of claim 2 , wherein the compound is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
6. A pharmaceutical composition comprising a compound of formula
wherein:
X is NH or O;
R 1 and R 2 are independently selected from H, halo, lower straight chain or branched alkyl, and OR 6 ;
R 3 , R 4 , and R 5 are independently selected from H, halo, —CN, lower straight chain or branched alkyl, and OR 6 ;
each R 6 is independently selected from H, lower straight chain or branched alkyl;
n is 1, 2 or 3;
the
group is substituted with 0, 1 or 2 groups independently selected from halo, —CN, lower straight chain or branched alkyl; and
at least one of R 3 , R 4 , or R 5 is in the ortho position and selected from the group consisting of halo, —CN, a straight chain or branched alkyl of 1 to 4 carbon atoms, and a straight or branched alkoxy of 1 to 4 carbon atoms;
or a pharmaceutically acceptable salt thereof;
and a pharmaceutically acceptable carrier.
7. The pharmaceutical composition of claim 6 , wherein the
group is
wherein:
R 8 is selected from H, halo and —CN.
8. The pharmaceutical composition of claim 7 , wherein at least two of R 3 , R 4 , or R 5 is in the ortho position and selected from the group consisting of halo, —CN, a straight chain or branched alkyl of 1 to 4 carbon atoms, and a straight or branched alkoxy of 1 to 4 carbon atom.
9. The pharmaceutical composition of claim 7 , wherein R 2 is selected from halo, lower straight chain or branched alkyl, and OR 6 .
10. The pharmaceutical composition of claim 7 , wherein the compound is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
11. The composition of claim 1 , wherein at least two of R 3 , R 4 , or R 5 is in the ortho position and selected from the group consisting of halo, —CN, a straight chain or branched alkyl of 1 to 4 carbon atoms, and a straight or branched alkoxy of 1 to 4 carbon atoms.
12. The composition of claim 1 , wherein R 2 is selected from halo, lower straight chain or branched alkyl, and OR 6 .
13. The pharmaceutical composition of claim 6 , wherein at least two of R 3 , R 4 , or R 5 is in the ortho position and selected from the group consisting of halo, —CN, a straight chain or branched alkyl of 1 to 4 carbon atoms, and a straight or branched alkoxy of 1 to 4 carbon atoms.
14. The pharmaceutical composition of claim 6 , wherein R 2 is selected from halo, lower straight chain or branched alkyl, and OR 6 .